Seelos Therapeutics Shares Set to Reverse Split on Friday, September 27th (NASDAQ:SEEL)

Seelos Therapeutics, Inc. (NASDAQ:SEEL) shares are scheduled to reverse split on the morning of Friday, September 27th. The 1-16 reverse split was announced on Wednesday, September 25th. The number of shares owned by shareholders will be adjusted after the closing bell on Thursday, September 26th.

Seelos Therapeutics Stock Performance

Seelos Therapeutics stock traded up $0.04 during mid-day trading on Wednesday, reaching $0.34. The stock had a trading volume of 29,494,923 shares, compared to its average volume of 2,727,255. Seelos Therapeutics has a one year low of $0.18 and a one year high of $53.04. The company has a 50-day moving average price of $0.31 and a two-hundred day moving average price of $1.73.

Seelos Therapeutics (NASDAQ:SEEL) last posted its quarterly earnings results on Wednesday, August 14th. The company reported $0.12 EPS for the quarter. The firm had revenue of $0.38 million for the quarter.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Seelos Therapeutics stock. Gendell Jeffrey L raised its position in shares of Seelos Therapeutics, Inc. (NASDAQ:SEEL) by 284.3% in the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 428,966 shares of the company’s stock after purchasing an additional 317,351 shares during the quarter. Gendell Jeffrey L owned 2.58% of Seelos Therapeutics worth $254,000 as of its most recent SEC filing. 23.37% of the stock is owned by hedge funds and other institutional investors.

About Seelos Therapeutics

Seelos Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system, respiratory, and other disorders. The company's lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for the treatment of patients with Parkinson's disease (PD).